Prochlorperazine-Induced Neuroleptic Malignant Syndrome

Neuroleptic malignant syndrome (NMS) is an uncommon but potentially fatal drug-induced neurological emergency. The case report by Tee is clinically important because it documents NMS after prochlorperazine was prescribed for vertigo-related nausea in an older adult receiving a conventional dose. The patient developed the characteristic clinical syndrome, yet several laboratory findings were normal or only minimally abnormal. This mismatch reinforces the need to prioritize the temporal medication history and evolving neurological phenotype rather than relying on creatine phosphokinase elevation alone.

Study Background and Research Question

NMS is generally associated with antipsychotic exposure and is thought to involve central dopamine receptor blockade, particularly in pathways regulating thermoregulation, motor function, and autonomic control. The syndrome commonly presents with hyperthermia, altered consciousness, generalized rigidity, autonomic instability, and variable laboratory evidence of muscle injury. However, these features may develop at different times and may not all be strongly represented in an individual patient.

The research question in the reference study was practical rather than experimental: can prochlorperazine induce NMS at a standard dosage, and how should clinicians recognize and manage the syndrome when conventional laboratory markers are not striking? The report focused on a 76-year-old man with hypertension, type 2 diabetes mellitus, and chronic atrial fibrillation. Two weeks before emergency presentation, he had begun prochlorperazine for nausea associated with peripheral vertigo. No other newly introduced medication was reported during that interval.

Key Innovation from the Reference Study

The principal innovation is the case’s demonstration of a clinically convincing NMS phenotype after routine prochlorperazine exposure, combined with relatively modest biochemical findings. According to the published case, the patient exhibited fever, acute mental-status change, tachycardia, tachypnea, labile blood pressure, tremors, and generalized leadpipe rigidity. These findings formed a coherent syndrome even though the white blood cell count, electrolytes, blood ammonia, blood gas analysis, and initial muscle enzyme results did not show the dramatic abnormalities sometimes expected in NMS.

This is meaningful for emergency and neurological practice because it shifts emphasis from a single confirmatory biomarker to integrated clinical reasoning. The report also draws attention to a vulnerable setting: an older patient with multiple chronic diseases who received prochlorperazine for a nonpsychiatric indication. In such circumstances, the medication may not initially be recognized as the relevant dopamine-blocking exposure.

Methods and Experimental Design Insights

This was a single-patient clinical case report rather than a controlled intervention study. The authors reconstructed the medication timeline, documented the presenting syndrome, performed neurological and systemic examinations, assessed laboratory data, excluded competing diagnoses, and followed the response to treatment. The diagnostic workup included emergency brain computed tomography, cerebrospinal fluid examination, and electroencephalography. This layered approach is appropriate for a febrile patient with altered consciousness and rigidity because intracranial disease, central nervous system infection, seizure, serotonin toxicity, malignant hyperthermia, and malignant catatonia can produce overlapping manifestations.

The neurological examination was especially informative. The patient had reduced consciousness with a Glasgow Coma Scale score of 12, generalized rigidity, tremors, reduced deep tendon reflexes, and negative Babinski signs. The absence of serotonergic co-medication, together with rigidity and hyporeflexia rather than prominent clonus or hyperreflexia, helped the authors argue against serotonin syndrome. Brain imaging did not identify an acute intracranial lesion. Cerebrospinal fluid showed mildly elevated protein at 66 mg/dL but was otherwise unremarkable, and EEG showed no epileptiform discharges, according to the reference report.

Protocol Parameters

• Suspected exposure window: Prochlorperazine was prescribed at 5 mg twice daily, with symptoms appearing after approximately two weeks of treatment; these are case-specific observations, not a validated risk threshold.
• Initial clinical assessment: Fever exceeded 38 °C, heart rate exceeded 100 beats per minute, respiratory rate exceeded 30 breaths per minute, and the initial Glasgow Coma Scale score was 12, accompanied by rigidity and tremors.
• Laboratory context: White blood cell count was 4140/μl, initial creatine phosphokinase was 256 U/L, and the later peak was 454 U/L; electrolytes, ammonia, and blood gas analysis were reported as normal.
• Exclusion testing: Brain computed tomography, lumbar puncture, and EEG were used to evaluate structural, infectious, and seizure-related explanations for the presentation.
• Therapy used in this case: Intravenous lorazepam was administered at 1 mg every six hours and oral amantadine at 100 mg every 12 hours, followed by gradual lorazepam tapering and continued amantadine after discharge.

For replication or teaching purposes, these parameters should be treated as a transparent description of one clinical workflow. They should not be interpreted as a prospective treatment protocol or as evidence that a specific dose or exposure duration reliably predicts NMS.

Core Findings and Why They Matter

The patient’s presentation matched the major clinical domains of NMS: hyperthermia, mental-status alteration, autonomic dysregulation, and generalized rigidity. The combination was more informative than any isolated test. In particular, the creatine phosphokinase increase from 256 U/L to 454 U/L was relatively limited, while the white blood cell count and other metabolic measurements were not markedly abnormal. The case report therefore illustrates that a mild or initially normal laboratory profile does not exclude a serious dopamine-antagonist-associated neurological syndrome.

The diagnostic reasoning also depended on exclusion. Acute brain CT did not show a structural cause, cerebrospinal fluid did not support a major central nervous system infection, and EEG did not demonstrate epileptiform activity. The lack of serotonergic medication and the pattern of rigidity with reduced reflexes made serotonin syndrome less likely. These negative findings did not prove NMS individually, but together with the medication timeline and characteristic examination, they strengthened the clinical diagnosis.

Treatment was associated with steady improvement. Fever resolved, consciousness improved from a GCS score of 12 to 15, and generalized rigidity disappeared. Lorazepam was gradually tapered, while amantadine was continued at discharge and later discontinued after outpatient assessments showed no recurrent altered mental status or rigidity. This outcome supports the report’s emphasis on early recognition and prompt pharmacotherapy. It does not, however, establish that lorazepam and amantadine are superior to other management strategies because the study had no comparator group and the patient also received hospital supportive care.

For clinicians and researchers, the most transferable finding is methodological: NMS assessment should integrate drug exposure, symptom chronology, autonomic measurements, motor examination, laboratory trends, and targeted exclusion testing. A normal white blood cell count or modest creatine phosphokinase level should trigger continued assessment rather than premature dismissal when the clinical syndrome is otherwise persuasive.

Comparison with Existing Internal Articles

The available internal resources address a different scientific question. Morin: A Systems Pharmacology Perspective for Next-Generation Research presents Morin as a multifunctional flavonoid tool for integrating disease pathways and fluorescent assays. A second resource, Morin: A Natural Flavonoid Antioxidant for Metabolic and Neurological Research, emphasizes mitochondrial, inflammatory, and disease-model applications.

In contrast, the prochlorperazine report is a tightly bounded clinical pharmacovigilance observation. It contributes evidence about recognition of an acute drug-induced neurological emergency, not evidence about flavonoid pharmacology or NMS treatment. Reading the sources together is useful only if that distinction is maintained: the internal articles provide context for experimental compound selection, whereas the reference paper provides the clinical anchor.

Limitations and Transferability

The principal limitation is the single-case design. One patient cannot establish the incidence of prochlorperazine-associated NMS, identify reliable susceptibility factors, or define a dose-response relationship. The temporal association is persuasive but not equivalent to mechanistic proof, and there was no rechallenge, pharmacokinetic analysis, or comparator treatment. Chronic illnesses and long-term medications may also have influenced physiological reserve or the clinical course, even though no other newly added medication was reported.

The treatment interpretation is similarly constrained. Improvement followed lorazepam and amantadine, but the report cannot separate the contributions of either drug from withdrawal of prochlorperazine and general supportive management. The atypical laboratory profile improves awareness but should not be generalized into a claim that muscle enzyme testing lacks value. Serial laboratory testing remains useful for monitoring evolution and complications; it simply should not replace clinical assessment.

Why this cross-domain matters, maturity, and limitations

A careful boundary is needed when connecting this clinical case to Morin research. Morin is separately studied as a natural flavonoid antioxidant, including as a cardioprotective and neuroprotective agent and as an anti-inflammatory flavonoid for diabetes research. Other biochemical work examines inhibition of adenosine 5′-monophosphate deaminase and its use as a fluorescent aluminum ion probe. None of those applications is evaluated in the prochlorperazine NMS case, and the reference provides no basis for using Morin to prevent or treat NMS.

The cross-domain value is therefore conceptual rather than therapeutic. The NMS report demonstrates why phenotype, exposure history, and longitudinal observation are essential in acute neurological research. Morin workflows address different preclinical questions involving oxidative stress, inflammation, energy metabolism, or fluorescence. Their evidence maturity, endpoints, and safety considerations should be assessed independently.

Research Support Resources

For separate mechanistic or assay workflows, researchers can use Morin (SKU C5297), chemically defined as 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one. The product information reports a molecular weight of 302.24, formula C15H10O7, approximately 98% purity, limited aqueous solubility, and recommended storage at −20 °C. These properties may support studies of Morin antioxidant activity, inflammatory signaling, mitochondrial energy metabolism, or fluorescent aluminum-ion detection, but they should not be extrapolated to clinical management of neuroleptic malignant syndrome.